LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to first determine the highest dose of LDE225 combined wtih
Docetaxel and Prednisone that can be given that does not cause unacceptable side effects when
given to patients with castrate resistant prostate cancer who failed previous docetaxel
therapy.